Gritstone Bio GRTS is a clinical-stage biotechnology company focused on developing vaccines targeting multiple indications, including cancer. In the past week, the company’s stock lost 57.5%. This ...

BTIG analyst Kaveri Pohlman maintained a Buy rating on Gritstone Oncology (GRTS – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $2.63. According ...

Gritstone bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. My name is Latonya and welcome to Gritstone ...

GRTS COVID-19 vaccine can use two components, a chimpanzee adenovirus ((ChAd)) and self-amplifying mRNA (samRNA). Pfizer (PFE) and BioNTech (BNTX) as well as Moderna (MRNA) both used mRNA in their ...

Gritstone bio (NASDAQ:GRTS) shares soared 23% in after-hours trading Wednesday following an announcement that the company had been awarded a US government contract worth up to $433M to test a ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Gritstone bio, Inc.